The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer

Prostate cancer is one of the most common malignant tumors in men. Initially, it is androgen-dependent, but it eventually develops into castration-resistant prostate cancer (CRPC), which is incurable with current androgen receptor signaling target therapy and chemotherapy. Immunotherapy, specificall...

Full description

Bibliographic Details
Main Authors: Pengfei Xu, Logan J. Wasielewski, Joy C. Yang, Demin Cai, Christopher P. Evans, William J. Murphy, Chengfei Liu
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biomedicines
Subjects:
prostate cancer
immunotherapy
immunosuppressive signaling
tumor immune microenvironment
checkpoint inhibitor
therapy resistance
Online Access:https://www.mdpi.com/2227-9059/10/8/1778

Internet

https://www.mdpi.com/2227-9059/10/8/1778

Similar Items